22 Stocks Moving in Wednesday’s Pre-Market Session
Gainers
CohBar, Inc. (NASDAQ: CWBR) shares rose 78.3% to $2.30 in pre-market trading after the company reported results from the Phase 1a/1b study of CB4211 under development for NASH and obesity met its primary endpoint. The company also released Q2 results.
SVB Leerink Maintains Outperform on Inari Medical, Lowers Price Target to $110
SVB Leerink analyst Danielle Antalffy maintains Inari Medical (NASDAQ:NARI) with a Outperform and lowers the price target from $126 to $110.
7 Stocks Moving In Tuesday’s After-Hours Session
Gainers
Upstart (NASDAQ: UPST) shares are trading higher after the company reported better-than-expected Q2 EPS and sales results and issued Q3 sales guidance above estimates. The company also raised FY21 sales guidance above estimates.
Inari Medical: Q2 Earnings Insights
Shares of Inari Medical (NASDAQ:NARI) decreased in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 143.75% year over year to $0.07, which missed the estimate of $0.08.
Inari Medical Q2 EPS $0.07 Misses $0.08 Estimate, Sales $63.50M Beat $59.65M Estimate
Inari Medical (NASDAQ:NARI) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.08 by 12.5 percent. This is a 143.75 percent increase over losses of $(0.16) per share from the
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck’s Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 9)
Earnings Scheduled For August 10, 2021
Companies Reporting Before The Bell
• Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.